Antibiotics Market, By Inhibitor Types (Protein Synthesis, Cell Wall, DNA, and RNA), By Drug Class (Fluoroquinolones, Cephalosporin, Penicillin, Macrolides, Carbapenems, Aminoglycosides) and Geography (NA, EU, APAC, and RoW) – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025

  • Product Code:
    RP-ID-10293921
  • Published Date:
    17 Jul 2021
  • Region:
    Global
  • Pages:
    102
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-48

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

REPORT HIGHLIGHT
The antibiotics market is estimated to represent a global market of USD 43.9 billion by 2017 with growth rate of 4.9%.

Market Dynamics

Across the world, the number of individuals suffering from chronic diseases is on the rise. As per the World Health Organization (WHO), chronic disease accounts for more than 60% of all deaths, i.e. 36 million deaths out of 57 million global deaths. Antibiotics are increasingly used in the management of infectious and chronic conditions such as asthma, cystic fibrosis, COPD, and others. Thereby, the demand for antibiotics is more likely to increase for the treatment of these disease conditions, as the incidences of chronic diseases pick up. Meanwhile, numerous national and international initiatives aimed at financially incentivizing the R&D activities of antibiotics. Some of the major initiatives are New Drugs for Bad Bugs (ND4BB) program by the Innovative Medicines Initiative (IMI), Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), and Broad Spectrum Antimicrobials Program and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). Such types of initiatives would, in turn, support the growth over the study period.

However, growing concern over antibiotic overuse is expected to hinder the industry growth to some extent. Overuse of these drugs may develop resistance to antimicrobial medications which is considered to be a serious public health threat to the world. According to the statement by European Centre for Disease Prevention and Control (ECDC) in November 2012, around 25,000 people die every year due to antibiotic-resistant bacterial infections in European countries.

Inhibitor Type Takeaway

By inhibitor types, the industry is divided into Protein Synthesis, Cell Wall, DNA, RNA, and other inhibitors. Cell wall synthesis inhibitors accounted for the highest share of the total market. In 2017, the segment captured around 42% share of the overall market and is projected to dominate the industry. This drug class includes antibiotics such as penicillin, cephalosporin, and Carbapenems. These are one of the most important groups of antibiotics and offers the greatest activity against gram-positive and negative bacteria. Cell wall synthesis inhibitors act by prohibiting the synthesis of the peptidoglycan layer, which is a crucial element for the structural activity of the cell wall. However, RNA segment is projected to grow with the highest growth rate and is pegged to register a 6.2% CAGR in terms of value.

Drug Class Takeaway

Drug class is categorized into Fluoroquinolones, Cephalosporin, Penicillin, Macrolides, Carbapenems, Aminoglycosides, and other. Growing by approximately 3% to 4% every year, cephalosporin drug class is the highest revenue generating segment throughout the study period. The growth of this bactericidal agent is majorly attributed to the rising demand for 4th and 5th generation therapeutics such as Ceftaroline fosamil, Cefpirome, and Ceftobiprole. On another side, aminoglycosides captured less than 5% share (i.e. lowest) of the global industry in 2017. Others segment comprise of tetracyclines, sulphonamides, monoclonal antibodies, imidazole, and many more.

Regional Takeaway

Regionally, Asia Pacific region is accounted for the largest share of the worldwide market. In 2017, the region captured almost 47% share of the overall market. Increasing prevalence of infectious and chronic diseases coupled with rising interest of global players to invest in this market support the regional growth. While the industry is on a high growth trajectory in developing regions, demand and advancement in regions like North America, and Europe is constantly increasing. Growth is mainly supported by the favorable reimbursement policies, rising demand for branded therapeutics, and increasing R&D activities.

Key Vendor Takeaway

Novartis AG, Johnson & Johnson, Pfizer, Inc., GlaxoSmithKline, Bayer AG, and AstraZeneca are studied in detail. The industry is largely controlled by well-established companies even though the share of small-scale players is noticeable too. Companies such as Johnson & Johnson, Pfizer, and Novartis are considered to be a giant player in this market owing to their strong product pipeline and strategic expansion.

For example, Pfizer, Inc. offers a broad range of antibiotics that includes Diflucan, Zithromax/Zmax, Unasyn, Vfend, Sulperazon, Tygacil, and others. Of these, in 2015, antibiotics such as Zyvox (USD 883 million), and Vfend (USD 682 million) recorded the highest revenue. The industry exhibits a high level of competition. Since the market is in the mature phase, barriers to entry are low. Still, in such a fragmented landscape, most antibiotic companies compete only with other local or regional players.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year – 2014 & 2016
Base Year – 2017
Estimated Year – 2018
Projected Year – 2025
TARGET AUDIENCE

Traders, Distributors, and Suppliers
Manufacturers
Hospitals
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY INHIBITOR TYPE

Protein Synthesis
Cell Wall
DNA
RNA
Others
MARKET, BY DRUG CLASS

Fluoroquinolones
Cephalosporin
Penicillin
Macrolides
Carbapenems
Aminoglycosides
Other
MARKET, BY REGION

North America
U.S.
Canada
Europe
Germany
France
Rest of Europe
Asia Pacific
India
China
Rest of APAC
Rest of the World
Middle East and Africa
Latin America


The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

  • North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys  & Opportunity Outlook
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook
  •  Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

TABLE OF CONTENT
1. ANTIBIOTICS MARKET OVERVIEW
1.1. Study Scope
1.2. Assumption and Methodology
2. EXECUTIVE SUMMARY
2.1. Key Market Facts
2.2. Geographical Scenario
2.3. Companies in the Market
3. ANTIBIOTICS KEY MARKET TRENDS
3.1. Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Market Opportunities
3.4. Market Future Trends
4. ANTIBIOTICS INDUSTRY STUDY
4.1. Porter’s Analysis
4.2. Market Attractiveness Analysis
4.3. Regulatory Framework Analysis
5. ANTIBIOTICS MARKET LANDSCAPE
5.1. Market Share Analysis
6. ANTIBIOTICS MARKET – BY INHIBITOR TYPES:
6.1. Overview
6.2. Protein Synthesis Inhibitors
6.2.1. Overview
6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.3. Cell Wall Inhibitors
6.3.1. Overview
6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.4. DNA Synthesis Inhibitors
6.4.1. Overview
6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.5. RNA Synthesis Inhibitors
6.5.1. Overview
6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
6.6. Others
6.6.1. Overview
6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7. ANTIBIOTICS MARKET – BY DRUG CLASS
7.1. Overview
7.2. Fluoroquinolones
7.2.1. Overview
7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.3. Cephalosporin
7.3.1. Overview
7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.4. Penicillin
7.4.1. Overview
7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.5. Macrolides
7.5.1. Overview
7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.6. Carbapenems
7.6.1. Overview
7.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.7. Aminoglycosides
7.7.1. Overview
7.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
7.8. Other
7.8.1. Overview
7.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8. ANTIBIOTICS MARKET– BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. Overview
8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.2.3. U.S.
8.2.3.1. Overview
8.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.2.4. Canada
8.2.4.1. Overview
8.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.3. Europe
8.3.1. Overview
8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.3.3. France
8.3.3.1. Overview
8.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.3.4. Germany
8.3.4.1. Overview
8.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.3.5. Rest of Europe
8.3.5.1. Overview
8.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.4. Asia Pacific (APAC)
8.4.1. Overview
8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.4.3. China
8.4.3.1. Overview
8.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.4.4. India
8.4.4.1. Overview
8.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.4.5. Rest of APAC
8.4.5.1. Overview
8.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.5. Rest of the World
8.5.1. Overview
8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.5.3. Latin America
8.5.3.1. Overview
8.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
8.5.4. Middle East and Africa
8.5.4.1. Overview
8.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 – 2025, (US$ Billion)
9. KEY VENDOR ANALYSIS
9.1. Novartis AG
9.1.1. Company Overview
9.1.2. SWOT Analysis
9.1.3. Key Developments
9.2. Johnson & Johnson
9.2.1. Company Overview
9.2.2. SWOT Analysis
9.2.3. Key Developments
9.3. Pfizer, Inc.
9.3.1. Company Overview
9.3.2. SWOT Analysis
9.3.3. Key Developments
9.4. GlaxoSmithKline, Inc.
9.4.1. Company Overview
9.4.2. SWOT Analysis
9.4.3. Key Developments
9.5. Bayer AG
9.5.1. Company Overview
9.5.2. SWOT Analysis
9.5.3. Key Developments
9.6. AstraZeneca plc
9.6.1. Company Overview
9.6.2. SWOT Analysis
9.6.3. Key Developments
*Client can request additional company profiling as per specific requirements
10. 360 DEGREE ANALYSTVIEW
11. APPENDIX
11.1. Research Methodology
11.2. Abbreviations
11.3. Disclaimer
11.4. Contact Us

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports